中富通(300560.SZ):擬出資4950萬元投設子公司富巖科技
格隆匯8月4日丨中富通(300560.SZ)公佈,公司於2021年8月4日召開第四屆董事會第四次會議審議並通過了《關於設立子公司的議案》,擬在北京設立子公司“北京富巖科技有限公司”(暫定名,以工商行政管理部門核准的名稱為準,“富巖科技”)。
富巖科技註冊資金5000萬元人民幣。其中公司擬以自有資金出資4950萬元,佔比99%,公司全資子公司福州富宇股權投資管理有限公司(“富宇投資”)出資50萬元,佔比1%。
公司此次設立富巖科技,擬用於開展軟件開發、信息系統集成等業務。新公司的設立,系公司發展的需要,符合公司的長遠規劃及發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.